GlassScriptPhysician profile
Paul A Chite
NPI 1164685145
$5,123.97
in general payments reported to CMS, 2019-2025
30 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $51.69 · 2021: $322 · 2022: $792 · 2023: $822 · 2024: $1,307 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,509.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,278.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $587.75 | 2021-2025 | Shingrix, Arexvy |
| Abbvie INC. | $419.87 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $419.40 | 2019-2025 | |
| Abbott Laboratories | $355.33 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $303.49 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $300.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $268.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $256.11 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.86 | 2019-2025 | Jardiance |
| Amgen INC. | $88.53 | 2019-2025 | Repatha, Otezla, Prolia |
| Lundbeck LLC | $80.71 | 2022-2025 | Vyepti |
| Astellas Pharma US INC | $77.80 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $64.39 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $53.07 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.47 | 2022-2023 | |
| Corcept Therapeutics | $40.09 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.70 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $36.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $36.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.43 | 2020-2023 | Xarelto |
| Medtronic, INC. | $30.49 | 2021-2023 | Closurefast |
| Bausch Health US, LLC | $29.00 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.11 | 2025 | Caplyta |
| Allergan, INC. | $18.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.82 | 2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.53 | 2022 | |
| Organon LLC | $16.31 | 2022 | |
| Esperion Therapeutics, INC. | $16.30 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.